

Catalogue  
Number

Product

Order number / Unit

**9775**

**Lu-DOTA-TATE**

Reference standard for <sup>177</sup>Lu-DOTA-TATE

**Molar Mass:** 1607.57

C<sub>65</sub>H<sub>187</sub>LuN<sub>14</sub>O<sub>19</sub>S<sub>2</sub> (net peptide)

CAS-RN not yet assigned

[<sup>177</sup>Lu]DOTA-TATE: [753443-19-5]

Colourless to off-white freeze-dried solid packaged in dark glass screw cap vials.

**Purity:** ≥ 95 %

**Certificates:**

CoA; MS (identity) and HPLC (purity)

**Chemical Name:**

Lutetate(1-)-, [N-[[4,7,10-tris[(carboxy-κO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threonine cyclic (2→7)-disulfidato(4-)]-


**Synonyms:**

Lu-DOTATATE; Lu-DOTA-[Tyr<sup>3</sup>]octreotate

**Literature:**

1. De Jong M. et al. [<sup>177</sup>Lu-DOTA<sup>0</sup>,TYR<sup>3</sup>]Octreotate for Somatostatin Receptor-Targeted Radionuclide Therapy. *Int. J. Cancer.* 2001, 92, 628-633.
2. Kwekkeboom D.J. et al. [<sup>177</sup>Lu-DOTA<sup>0</sup>,Tyr<sup>3</sup>]octreotate: comparison with [<sup>111</sup>In]-DTPA<sup>0</sup>-octreotide in patients. *Eur. J. Nucl. Med.* 2001, 28, 1319-1325.

**9775.0001: 1 mg per vial**  
**9775.0010: 10 mg per vial**  
**Please inquire for customized filling and bulk quantities.**



date of product catalogue issue: 05 April 2012